Biogen Inc. Common Stock
Compare this stock
BIIB Stock Report Card
$
58%
Performance
Score:
74/100
BIIB returned -15.64% in the last 12 months. Based on SPY's performance of -20.65%, its performance is above average giving it a score of 74 of 100.
Analyst Price Targets
Score:
73/100
32 analysts offer 12-month price targets for BIIB. Together, they have an average target of 294.73, the most optimistic target put BIIB at 405 within 12-months and the most pessimistic has BIIB at 209.
Sentiment
Score:
70/100
BIIB had a bullish sentiment score of 70.25% across Twitter and StockTwits over the last 12 months. It had an average of 66.53 posts, 492.48 comments, and 835.41 likes per day.
Technicals
Score:
14/100
BIIB receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
Earnings
Score:
61/100
BIIB has missed earnings 2 times in the last 20 quarters.
Profit
Score:
64/100
Out of the last 20 quarters, BIIB has had 19 profitable quarters and has increased their profits year over year on 6 of them.
Volatility
Score:
40/100
BIIB has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.
Biogen Inc. Common Stock Summary
Nasdaq / BIIB
Healthcare
Drug Manufacturers - General
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
BIIB scored highly on our reportcard. Here are some similar companies and how they performed.